文献速递膀胱癌与上尿路尿路上皮癌

致癌驱动基因改变是否导致一线晚期尿路上皮癌免疫治疗疗效不佳

Can Oncogenic Driver Alterations be Responsible for the Lack of Immunotherapy Efficacy in First-line Advanced Urothelial Carcinoma?
PubMed 文献 · Eur Urol · 2022-05-20

尿路上皮癌(UC)携带多种致癌改变,一线免疫治疗疗效有限,提示致癌改变可能作为治疗决策的预测生物标志物。抗体药物偶联物(ADC)或为晚期UC尤其携带致癌改变患者提供生物标志物驱动治疗的新途径。

要点

  • UC携带多种致癌改变,一线免疫治疗疗效有限,提示致癌改变或可作为预测生物标志物。
  • ADC可能为晚期UC尤其致癌改变患者提供生物标志物驱动治疗新途径。

核心结论

  • 致癌改变可能作为一线免疫治疗决策的预测生物标志物,ADC或为携带致癌改变的晚期UC患者提供新治疗途径。

主要发现

  • UC携带多种致癌改变,一线免疫治疗在该背景下疗效有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Urothelial carcinoma (UC) harbors many oncogenic alterations and the limited efficacy of first-line immunotherapy in this setting suggests that oncogenic alterations could have potential as a predictive biomarker for treatment decision-making. Antibody-drug conjugates (ADCs) may offer new avenues for biomarker-driven treatment in advanced UC, especially for patients with oncogenic alterations.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Kartolo A, Robinson A, Vera Badillo FE, et al. Can Oncogenic Driver Alterations be Responsible for the Lack of Immunotherapy Efficacy in First-line Advanced Urothelial Carcinoma? Eur Urol. 2022. PMID: 35606230. doi:10.1016/j.eururo.2022.04.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。